Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram

NCT01639482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-03-07

No results posted yet for this study

Summary

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).

Conditions

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Darin D Dougherty, MD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639482 on ClinicalTrials.gov